Your browser doesn't support javascript.
loading
Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia.
Reddel, Helen K; Beckert, Lutz; Moran, Angela; Ingham, Tristram; Ampon, Rosario D; Peters, Matthew J; Sawyer, Susan M.
Afiliación
  • Reddel HK; Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.
  • Beckert L; Department of Medicine, University of Otago, Christchurch, New Zealand.
  • Moran A; Respiratory Services, Canterbury District Health Board, Christchurch, New Zealand.
  • Ingham T; Respiratory Services, Canterbury District Health Board, Christchurch, New Zealand.
  • Ampon RD; Department of Medicine, University of Otago, Wellington, New Zealand.
  • Peters MJ; Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.
  • Sawyer SM; Department of Respiratory Medicine, Concord Hospital and Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.
Respirology ; 22(8): 1570-1578, 2017 11.
Article en En | MEDLINE | ID: mdl-28791752
BACKGROUND AND OBJECTIVE: New Zealand (NZ) and Australia (AU) have similarly high asthma prevalence; both have universal public health systems, but different criteria for subsidized medicines. We explored differences in asthma management and asthma-related outcomes between these countries. METHODS: A web-based survey was administered in AU (2012) and NZ (2013) to individuals aged ≥16 years with current asthma, drawn randomly from web-based panels, stratified by national population proportions. Symptom control was assessed with the Asthma Control Test (ACT). Healthcare utilization was assessed from reported urgent doctor/hospital visits in the previous year. RESULTS: NZ (n = 537) and Australian (n = 2686) participants had similar age and gender distribution. More NZ than Australian participants used inhaled corticosteroid (ICS)-containing medication (68.8% vs 60.9%; P = 0.006) but ICS/long-acting ß2 -agonist (LABA) constituted 44.4% of NZ and 81.5% of Australian total ICS use (P < 0.0001). Adherence was higher with ICS/LABA than ICS-alone (P < 0.0001), and higher in NZ than in AU (P < 0.0001). ACT scores were similar (P = 0.41), with symptoms well controlled in 58.6% and 54.4% participants, respectively. More NZ participants reported non-urgent asthma reviews (56.6% vs 50.4%; P = 0.009). Similar proportions had urgent asthma visits (27.9% and 28.6%, respectively, P = 0.75). CONCLUSION: This comparison, which included the first nationally representative data for asthma control in NZ, showed that poorly controlled asthma is common in both NZ and AU, despite subsidized ICS-containing medications. The greater use of ICS-alone in NZ relative to ICS/LABA does not appear to have compromised population-level asthma outcomes, perhaps due to better adherence in NZ. Different ICS/LABA subsidy criteria and different patient copayments may also have contributed to these findings.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Asma / Agonistas de Receptores Adrenérgicos beta 2 / Glucocorticoides Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Oceania Idioma: En Revista: Respirology Año: 2017 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Asma / Agonistas de Receptores Adrenérgicos beta 2 / Glucocorticoides Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Oceania Idioma: En Revista: Respirology Año: 2017 Tipo del documento: Article País de afiliación: Australia